Blog Layout

No better time, no better choice of career

Josie Downey

The Managing Director of Merck Healthcare ANZ reflects on an exciting career in science and provides advice to new STEM graduates looking to make a difference. 

For graduates of the STEM disciplines, there may be no better career choice than the biopharmaceutical industry. That is one of the many lessons I have learned in the course of three decades working in life sciences.

 

As a science graduate, I didn’t pursue a career in the pharmaceutical sector. In fact it was the furthest thing from my mind. I knew very little about the industry and, if I’m honest, the prospect of joining it did not particularly excite me. Had it not been for a stroke of serendipity, my career would almost certainly have taken a different path.

 

Thirty years later, I consider myself incredibly fortunate to have fallen into an industry that continues to advance human health so rapidly and profoundly. I work in an industry in which career opportunities are limitless for people with a passion for science and patient wellbeing.

 

As we enter a post-COVID pandemic world, I would like to think that the life sciences would now top the list of employment sectors for not only STEM graduates but for anyone who is passionate about science and the opportunity to make a difference to people’s lives.

 

Without question, the pandemic has shone a spotlight on the often-overlooked ability of the biopharmaceutical sector to deliver not only life-changing and life-saving medical advances for individual patients, but to deliver untold social and economic benefits.

 

A likely flow-on effect of this will be increasing numbers of STEM graduates and professionals in the early stages of their careers seeking employment in this dynamic industry.

 

The biopharmaceutical sector is already fortunate to attract a large number of STEM graduates, often with majors in chemistry, physics, biochemistry, medical sciences, chemical and biomedical engineering and even maths. For analytic minds, career opportunities in biopharmaceuticals are endless, and I am just one of many, many example of that.

 

It was not long ago that the worlds of academia and industry were very clearly delineated. These days, those lines are much more blurred and old notions about differences in the ‘quality of science’ have all but gone. Collaborations between the biopharmaceutical industry and academic institutes are commonplace, with the shared goal of addressing unmet medical needs as best and quickly as possible. 

 

One of the greatest differences I have observed in the scientific pursuits of companies and academia is the timelines in which innovations are progressed and accomplished. Drug discovery is being accelerated because we invest so heavily in research and development. In fact, there are now more than 7,800 products in clinical development globally, with nearly 70 per cent of clinical projects focused on potential first-in-class therapies.1

 

Only through sustained investment in the long and often fraught road to drug discovery has it been possible to increase life expectancy so significantly over the past 30 years.

 

During my career, I have had the privilege to work on the development and introduction of life-saving and life-improving medicines for medical needs as diverse as infectious diseases and cancer to fertility issues, diabetes and cardiovascular disease.

 

One of the greatest highlights and honours of my career was leading a team that introduced an entirely new way of treating cancer. We did this resolute that no patient should be left behind. That is what the biopharmaceutical industry is really all about – harnessing scientific and medical innovation for the benefit of people we will most likely never meet.

 

I have come to realise that, like many of my colleagues and peers, the scientist in me loves being at the forefront of transformational medical innovation. But what really gets people in this sector out of bed every morning is knowing that these advances, and what we do with them, help Australian families live better, healthier and longer lives. Nothing is more rewarding.

 

A career in biopharmaceuticals comes with the opportunity to help advance medical practice; work closely with doctors; inform, coordinate or undertake clinical research; and have direct access to the earliest clinical data, allowing for important analysis of how it could affect clinical practice.

 

It also comes with the significant opportunity for progression – regardless of gender, sexuality, colour or creed. The pharmaceutical sector is steadfast in its commitment to remove barriers to diversity, equity and inclusion for the benefit or all. And this is one of the major reasons why I believe life sciences hold such strong prospects for female STEM graduates. As an industry, we are leading the way on gender equity.

 

My advice to STEM graduates and those early in their science career is to:

  • Be confident, curious and open to new opportunities.
  • Thoroughly explore the range of career options available to you. The job you have long dreamed of may not prove the right fit.
  • Avoid limiting your employment search to roles traditionally deemed suitable based on your study major, experience or gender. The world is your oyster.
  • Seek strong mentors and sponsors. Secure them early in your career and maintain these relationships as your career progresses.
  • And finally, seriously consider a career in the biopharmaceutical industry. It is full of opportunity and immensely rewarding. 

 

A graduate-level role within a biopharmaceutical company can be the first step to a successful and varied career here in Australia and overseas. I am one example of that. Will you be the next?

 

References: 1. Pharmaceutical Research and Manufacturers of America (PhRMA). Innovation in the Biopharmaceutical Pipeline. December 2021. Available at: https://phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-Org/PDF/G-I/Innovation_in_Biopharmaceuticals.pdf

 


Josie Downey is Managing Director of Merck Healthcare Australia and New Zealand.


By By Harley Paroulaksis, CEO Paspalis, CEO Darwin Innovation Hub 20 May, 2023
Getting asked what we look for in deals is one of the most common questions I get as an investment manager.
20 May, 2023
The Small Business Association of Australia is dedicated to supporting SMEs, acting as their voice to government and helping them connect, grow, and prosper well into the future.
By By Shiv Meka 20 May, 2023
Sensibles may sound like science fiction, but this revolutionary technology is making waves in aged-care facilities, and has the potential to transform health monitoring at scale.
28 Mar, 2023
Alice Springs and the deserts of Central Australia don’t sound like a food basket, but they are for businesswoman and bush foods innovator Rayleen Brown.
By Gillian Cumming 28 Mar, 2023
A new report aims to lay the foundations for a deeper and more meaningful and equitable relationship between Indigenous and non-Indigenous Australians in the mining transition sector.
By Dr Saraid Billiards - CEO of the Association of Australian Medical Research Institutes. 27 Mar, 2023
If the health and medical research sector in Australia is to move forward, it must address gender equity, diversity, and inclusion- which means making the sector a safe and inclusive workspace for all.
27 Jan, 2023
A ground-breaking sheep technology system is bettering the businesses and lives of Australian sheep breeders thanks to a revolutionary combination of software, hardware, and support never before combined into one cohesive unit.
27 Jan, 2023
ANCA took an early view to look beyond Australia’s shores whilst developing advanced manufacturing technologies now viewed as ‘business as usual’
By Andrew Downs 27 Jan, 2023
As Australia grapples with a critical skills shortage, many are now encouraging young people to embrace a career in the trades, where a wealth of opportunities awaits.
By By Ben Kehoe 27 Jan, 2023
In 2016 I published a blog article titled Moonshots for Australia: 7 For Now. It’s one of many I have posted on business and innovation in Australia. In that book, I highlighted a number of Industries of the Future among a number of proposed Moonshots. I self-published a book, Innovation in Australia – Creating prosperity for future generations, in 2019, with a follow-up COVID edition in 2020. There is no doubt COVID is causing massive disruption. Prior to COVID, there was little conversation about National Sovereignty or supply chains. Even now, these topics are fading, and we remain preoccupied with productivity and jobs! My motivation for this writing has been the absence of a coherent narrative for Australia’s business future. Over the past six years, little has changed. The Australian ‘psyche’ regarding our political and business systems is programmed to avoid taking a long-term perspective. The short-term nature of Government (3 to 4-year terms), the short-term horizon of the business system (driven by shareholder value), the media culture (infotainment and ‘gotcha’ games), the general Australian population’s cynical perspective and a preoccupation with a lifestyle all create a malaise of strategic thinking and conversation. Ultimately, it leads to a leadership vacuum at all levels. In recent years we have seen the leadership of some of our significant institutions failing to live up to the most basic standards, with Royal Commissions, Inquiries and investigations consuming excessive time and resources. · Catholic Church and other religious bodies · Trade Unions · Banks (and businesses generally, take casinos, for example) · the Australian Defence Force · the Australian cricket teams · our elected representatives and the staff of Parliament House As they say, “A fish rots from the head!” At best, the leadership behaviour in those institutions could be described as unethical and, at worst….just bankrupt! In the last decade, politicians have led us through a game of “leadership by musical chairs” – although, for now, it has stabilised. However, there is still an absence of a coherent narrative about business and wealth creation. It is a challenge. One attempt to provide such a narrative has been the Intergenerational Reports produced by our federal Government every few years since 2002. The shortcomings of the latest Intergenerational Report Each Intergenerational Report examines the long-term sustainability of current government policies and how demographic, technological, and other structural trends may affect the economy and the budget over the next 40 years. The fifth and most recent Intergenerational Report released in 2021 (preceded by Reports in 2002, 2007, 2010 and 2015) provides a narrative about Australia’s future – in essence, it is an extension of the status quo. The Report also highlights three key insights: 1. First, our population is growing slower and ageing faster than expected. 2. The Australian economy will continue to grow, but slower than previously thought. 3. While Australia’s debt is sustainable and low by international standards, the ageing of our population will pressure revenue and expenditure. However, its release came and went with a whimper. The recent Summit on (what was it, Jobs and Skills and productivity?) also seems to have made the difference of a ‘snowflake’ in hell in terms of identifying our long-term challenges and growth industries. Let’s look back to see how we got here and what we can learn. Australia over the last 40 years During Australia’s last period of significant economic reform (the late 1980s and early 1990s), there was a positive attempt at building an inclusive national narrative between Government and business. Multiple documents were published, including: · Australia Reconstructed (1987) – ACTU · Enterprise Bargaining a Better Way of Working (1989) – Business Council of Australia · Innovation in Australia (1991) – Boston Consulting Group · Australia 2010: Creating the Future Australia (1993) – Business Council of Australia · and others. There were workshops, consultations with industry leaders, and conferences across industries to pursue a national microeconomic reform agenda. Remember these concepts? · global competitiveness · benchmarking · best practice · award restructuring and enterprising bargaining · training, management education and multiskilling. This agenda was at the heart of the business conversation. During that time, the Government encouraged high levels of engagement with stakeholders. As a result, I worked with a small group of training professionals to contribute to the debate. Our contribution included events and publications over several years, including What Dawkins, Kelty and Howard All Agree On – Human Resources Strategies for Our Nation (published by the Australian Institute of Training and Development). Unfortunately, these long-term strategic discussions are nowhere near as prevalent among Government and industry today. The 1980s and 1990s were a time of radical change in Australia. It included: · floating the $A · deregulation · award restructuring · lowering/abolishing tariffs · Corporatisation and Commercialisation Ross Garnaut posits that the reforms enabled Australia to lead the developed world in productivity growth – given that it had spent most of the 20th century at the bottom of the developed country league table. However, in his work, The Great Reset, Garnaut says that over the next 20 years, our growth was attributable to the China mining boom, and from there, we settled into “The DOG days” – Australia moved to the back of a slow-moving pack! One unintended consequence of opening our economy to the world is the emasculation of the Australian manufacturing base. The manic pursuit of increased efficiency, lower costs, and shareholder value meant much of the labour-intensive work was outsourced. Manufacturing is now less than 6% of our GDP , less than half of what it was 30 years ago!
More Posts
Share by: